- Vale has reduced its forecast for 2025 capital expenditure to a range of $5.4 billion to $5.7 billion, down from the previous estimate of $5.9 billion.
- The company has introduced a sales estimate for a new product called “Carajás Médio Teor.” The sales forecast for 2025 is approximately 25 million tonnes.
- In addition, Vale provided a sales estimate for the concentrated product “PFC,” projecting about 24 million tonnes in sales for 2025.
- Market analysts have issued 11 buy ratings and 5 hold ratings on Vale’s stock, with no sell ratings reported.
A look at Vale Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Vale’s long-term outlook appears promising. The company scores high in Dividend, Resilience, and Momentum, indicating strong performance in these areas. With a solid dividend score of 5, Vale is likely to provide consistent and attractive returns to its shareholders over time. Its resilience score of 4 suggests that the company is well-positioned to weather economic uncertainties and market fluctuations. Additionally, the momentum score of 4 highlights Vale’s current positive trend and potential for future growth.
Vale S.A., a Brazilian company, focuses on the production and sale of various commodities including iron ore, manganese, gold, and nickel. With its diversified portfolio, Vale is able to navigate market challenges and capture opportunities across different sectors. Investors may find Vale an attractive long-term investment option given its strong dividend performance, resilience to market conditions, and promising growth prospects in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
